Individualization of mycophenolate mofetil dose in renal transplant recipients

Expert Opinion on Pharmacotherapy
Reinier M van HestTeun van Gelder

Abstract

The immunosuppressive agent mycophenolate mofetil has been successfully used over the past 10 years to prevent acute allograft rejection after renal transplantation. It has mainly been administered as a fixed dose of mycophenolate mofetil 1000 mg b.i.d. The pharmacokinetics of mycophenolic acid, the active moiety of the prodrug mycophenolate mofetil, show large between-patient variability, and exposure to mycophenolic acid correlates with the risk for acute rejection. This suggests that already excellent clinical results can be further improved by mycophenolate mofetil dose individualization. This review discusses different arguments in favour of individualization of mycophenolate mofetil dose, as well as strategies for managing mycophenolate mofetil therapy individualization, including pharmacokinetic and pharmacodynamic monitoring and dose individualization based on pharmacogenetic information. It is expected that pharmacokinetic monitoring of mycophenolic acid will offer the most effective and feasible tool for mycophenolate mofetil dose individualization.

References

Jan 1, 1993·Springer Seminars in Immunopathology·A C Allison, E M Eugui
Jun 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C C PaulusmaR P Oude Elferink
Jul 1, 1998·Clinical Pharmacokinetics·R E BullinghamB R Kamm
Jan 1, 1999·Clinical Pharmacology and Therapeutics·M D HaleG A Verpooten
Jul 7, 1999·Journal of Clinical Pharmacology·B KaplanL M Shaw
Dec 1, 1999·Clinical Pharmacology and Therapeutics·A G JohnsonD Nicol
Apr 25, 2000·Therapeutic Drug Monitoring·G Filler, I Mai
Nov 30, 2000·Journal of the American Society of Nephrology : JASN·Herwig-Ulf Meier-KriescheBruce Kaplan
Jan 13, 2001·Clinical Chemistry and Laboratory Medicine : CCLM·K BuddeH H Neumayer
Feb 17, 2001·Clinical Pharmacology and Therapeutics·M MoriiM Shibakawa
Feb 24, 2001·Therapeutic Drug Monitoring·L PouL Capdevila
Jan 5, 2002·Drug Metabolism Reviews·M B FisherS A Wrighton
Jan 24, 2002·Therapeutic Drug Monitoring·Leslie M ShawArthur Nawrocki
Apr 23, 2002·Pharmacogenomics·Howard L McLeod, Chokkalingam Siva
Aug 8, 2002·Kidney International·Dario CattaneoGiuseppe Remuzzi
Dec 21, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Herwig-Ulf Meier-KriescheBruce Kaplan
Feb 7, 2003·The New England Journal of Medicine·William E Evans, Howard L McLeod

❮ Previous
Next ❯

Citations

Jun 24, 2008·European Journal of Clinical Pharmacology·L'aurelle A JohnsonPamala A Jacobson
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·Brenda C M de WinterTeun van Gelder
Jan 8, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Randy M WindreichRaman Venkataramanan
Oct 30, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Fawzy A Elbarbry, Ahmed S Shoker
May 8, 2007·Clinical Biochemistry·Fawzy A Elbarbry, Ahmed S Shoker
Feb 26, 2008·Journal of Clinical Pharmacology·Pamala JacobsonPaul J Orchard
Jun 26, 2014·Transplant International : Official Journal of the European Society for Organ Transplantation·Pengmei LiTeun van Gelder
Nov 21, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pamala A JacobsonDaniel Weisdorf
Mar 9, 2018·Pharmacogenomics·Huan-Yu MengHuan Yang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
R BorrowsD Taube
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Teun van Gelder
© 2021 Meta ULC. All rights reserved